$APVO (APTEVO THERAPEUTICS) — 8-K: Aptevo Advances Lead Trispecific APVO451 Toward IND-Enabling Studies in 1H2027

Aptevo reported progress in its next-generation trispecific programs, optimizing several candidates for scalable manufacturing. The company expects to enter Investigational New Drug-enabling studies for its lead trispecific candidate, APVO451, in the first half of 2027. Trispecifics combine three complementary cancer-fighting functions in one molecule. Aptevo expects to present additional details at an upcoming international scientific conference.

Aptevo reported progress in its next-generation trispecific programs, optimizing several candidates for scalable manufacturing. The company expects to enter Investigational New Drug-enabling studies f